Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl
Drugs targeting the renin-angiotensin-aldosterone system (RAAS) are the mainstay of therapy to retard the progression of proteinuric chronic kidney disease (CKD) such as diabetic nephropathy. However, diabetic nephropathy is still the first cause of end-stage renal disease. New drugs targeted to the...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2012/321714 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559230718050304 |
|---|---|
| author | Jorge Rojas-Rivera Alberto Ortiz Jesus Egido |
| author_facet | Jorge Rojas-Rivera Alberto Ortiz Jesus Egido |
| author_sort | Jorge Rojas-Rivera |
| collection | DOAJ |
| description | Drugs targeting the renin-angiotensin-aldosterone system (RAAS) are the mainstay of therapy to retard the progression of proteinuric chronic kidney disease (CKD) such as diabetic nephropathy. However, diabetic nephropathy is still the first cause of end-stage renal disease. New drugs targeted to the pathogenesis and mechanisms of progression of these diseases beyond RAAS inhibition are needed. There is solid experimental evidence of a key role of oxidative stress and its interrelation with inflammation on renal damage. However, randomized and well-powered trials on these agents in CKD are scarce. We now review the biological bases of oxidative stress and its role in kidney diseases, with focus on diabetic nephropathy, as well as the role of the Keap1-Nrf2 pathway and recent clinical trials targeting this pathway with bardoxolone methyl. |
| format | Article |
| id | doaj-art-a6baac099e4c48748810fedf8d134220 |
| institution | Kabale University |
| issn | 2090-214X 2090-2158 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-a6baac099e4c48748810fedf8d1342202025-02-03T01:30:33ZengWileyInternational Journal of Nephrology2090-214X2090-21582012-01-01201210.1155/2012/321714321714Antioxidants in Kidney Diseases: The Impact of Bardoxolone MethylJorge Rojas-Rivera0Alberto Ortiz1Jesus Egido2Laboratory of Renal and Vascular Pathology, Division of Nephrology and Hypertension, IIS Fundación Jiménez Díaz, Autonoma University of Madrid, 28040 Madrid, SpainLaboratory of Renal and Vascular Pathology, Division of Nephrology and Hypertension, IIS Fundación Jiménez Díaz, Autonoma University of Madrid, 28040 Madrid, SpainLaboratory of Renal and Vascular Pathology, Division of Nephrology and Hypertension, IIS Fundación Jiménez Díaz, Autonoma University of Madrid, 28040 Madrid, SpainDrugs targeting the renin-angiotensin-aldosterone system (RAAS) are the mainstay of therapy to retard the progression of proteinuric chronic kidney disease (CKD) such as diabetic nephropathy. However, diabetic nephropathy is still the first cause of end-stage renal disease. New drugs targeted to the pathogenesis and mechanisms of progression of these diseases beyond RAAS inhibition are needed. There is solid experimental evidence of a key role of oxidative stress and its interrelation with inflammation on renal damage. However, randomized and well-powered trials on these agents in CKD are scarce. We now review the biological bases of oxidative stress and its role in kidney diseases, with focus on diabetic nephropathy, as well as the role of the Keap1-Nrf2 pathway and recent clinical trials targeting this pathway with bardoxolone methyl.http://dx.doi.org/10.1155/2012/321714 |
| spellingShingle | Jorge Rojas-Rivera Alberto Ortiz Jesus Egido Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl International Journal of Nephrology |
| title | Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl |
| title_full | Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl |
| title_fullStr | Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl |
| title_full_unstemmed | Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl |
| title_short | Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl |
| title_sort | antioxidants in kidney diseases the impact of bardoxolone methyl |
| url | http://dx.doi.org/10.1155/2012/321714 |
| work_keys_str_mv | AT jorgerojasrivera antioxidantsinkidneydiseasestheimpactofbardoxolonemethyl AT albertoortiz antioxidantsinkidneydiseasestheimpactofbardoxolonemethyl AT jesusegido antioxidantsinkidneydiseasestheimpactofbardoxolonemethyl |